Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Melinta Therapeutics logo — Unparalleled in Passion & Purpose

Melinta Therapeutics

Unparalleled in Passion & Purpose

Founded 2000 United States United States 156 employees Post-IPO Equity Total: $877.40M Biotechnology, Health Care +1

General Information

Company Name Melinta Therapeutics
Founded Year 2000
Location United States United States
Employees 156
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Melinta Therapeutics. To contact Melinta Therapeutics, visit melinta.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Melinta Therapeutics compare?

A PDF of Melinta Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Melinta Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Melinta Therapeutics

Melinta Therapeutics is a biotechnology company that prides itself on being unparalleled in passion and purpose. The company's high touch and big impact approach sets it apart, with a focus on agility and dedication to adding value at every turn. Melinta's culture is built on tenacity, brilliance, resilience, excellence, and courage, showcasing an unwavering resolve and a commitment to taking responsibilities seriously. Founded in 2000, the company operates in the biotechnology, health care, and pharmaceutical industries, with its headquarters located in the United States. Its last investment amounted to $123.20M in Post-IPO Equity, secured on 30 May 2018. Melinta is poised for significant growth, aiming to meet the unmet needs of patients collaboratively and believes in the power of diverse teams for meaningful impact. This company is one to watch, as it strives to make legendary strides in its field, recognizing that every step counts.

Business keywords: pharmaceuticals, antibiotics, drug development, infectious diseases, public health, drug-resistant infections, clinical trials, investor-backed, life sciences, healthcare startups, acute care, patient-centered care

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $123.20M -
30 May 2018
Grant $6.20M 1
CARB-X
CARB-X
07 May 2018
Post IPO Debt $240.00M 1
Deerfield
29 Nov 2017
Post IPO Equity $90.00M 1
Oberland Capital
Oberland Capital
29 Jun 2017
Post IPO Equity $67.00M 2
Vatera Healthcare Partners
Vatera Healthcare Partners, Malin Corporation
10 Jun 2015
Post IPO Debt $30.00M 1
Hercules Capital
Hercules Capital
09 Feb 2015
Post IPO Equity $70.00M 2
Vatera Healthcare Partners
Vatera Healthcare Partners, Falcon Flight
10 Feb 2014
Post IPO Equity $67.50M 4
ABS Ventures Warburg Pincus Vatera Healthcare Partners
ABS Ventures, Warburg Pincus +2
29 Nov 2012
Post IPO Equity $3.00M 1
Sanofi
07 Feb 2012
Series E $20.00M 1
Warburg Pincus
Warburg Pincus
11 Jan 2011

View All 14 Funding Rounds

Melinta Therapeutics Alternatives & Competitors

View All Alternatives
Melinta Therapeutics vs
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals United States

Fighting against antimicrobial resistance is at the core of our technology and our people.

Grant
14 employees
Biopharma, Biotechnology
Compare Melinta Therapeutics vs Tetraphase Pharmaceuticals
Melinta Therapeutics vs
Synereca Pharmaceuticals
Synereca Pharmaceuticals

Pioneering orally active drugs to rejuvenate antibiotic efficacy against lung, urinary tract, and sk...

Venture round
Biotechnology, Health Care
Compare Melinta Therapeutics vs Synereca Pharmaceuticals
Melinta Therapeutics vs
Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd Australia

Recce Pharmaceuticals (ASX:RCE) is pioneering a New Class of Synthetic Anti-Infectives to combat AMR...

Grant
19 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Melinta Therapeutics

Unparalleled in Passion & Purpose
Melinta Therapeutics was founded in 2000.
Melinta Therapeutics is headquartered in United States.
Melinta Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, antibiotics, drug development and infectious diseases.
Melinta Therapeutics has approximately 156 employees.
Melinta Therapeutics has completed 14 funding rounds, raising a total of $877.40M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Melinta Therapeutics include Tetraphase Pharmaceuticals, Synereca Pharmaceuticals, Recce Pharmaceuticals Ltd, Zikani Therapeutics, MicuRx Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Melinta Therapeutics and Tetraphase Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Melinta Therapeutics, https://bouncewatch.com/company/melinta-therapeutics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout